UK markets closed
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • FTSE 250

    22,734.13
    +125.37 (+0.55%)
     
  • AIM

    1,249.65
    +3.03 (+0.24%)
     
  • GBP/EUR

    1.1648
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • BTC-GBP

    25,433.72
    -396.46 (-1.53%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.36 (+0.04%)
     
  • CRUDE OIL

    70.78
    +0.49 (+0.70%)
     
  • GOLD FUTURES

    1,879.50
    -16.90 (-0.89%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     
  • HANG SENG

    28,842.13
    +103.25 (+0.36%)
     
  • DAX

    15,693.27
    +122.05 (+0.78%)
     
  • CAC 40

    6,600.66
    +54.17 (+0.83%)
     

Mental Disorder Drugs Market size worth US$58.91 Billion by 2031. Visiongain Research Inc.

·5-min read

Visiongain has published a new report on Mental Disorder Drugs Market Report 2021-2031. Profiles of Mental Disorder Drugs and Forecasts. By Drug Class (SSRIs, SNRIs, Atypical Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs), By Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy). PLUS Regional Market Analysis and COVID-19 Recovery Scenarios.

Visiongain’s lead analyst says: ‘The Global mental disorder drugs market was valued at US$ US$36.77 bn in 2020 and is projected to reach at a market value of US$58.91 billion by 2031. Rising prevalence of mental disorders; mounting investment in drug R&D by pharmaceutical & biopharmaceutical companies; growing mental health care awareness; new product launches and rising acceptance of mental disorder drugs worldwide are some of the major factors that propel the global mental disorder drugs market growth’.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/mental-disorder-drugs-market-2021/#download_sampe_div

How this report will benefit you


Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit soon. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.

How has COVID-19 Impacted the Mental Disorder Drugs Market?

The COVID-19 pandemic has a mixed impact on the mental disorder drugs market worldwide. The COVID-19 pandemic has resulted in the increasing prevalence of mental disorders worldwide. However, the pharmaceutical and biologics companies are facing challenges while drug manufacturing and marketing due to the COVID-19 pandemic. According to the WHO, the COVID-19 pandemic has disturbed the mental healthcare services in many countries.

Thus, the demand for these drugs impacted negatively since 2020. However, the market is expected to lucrative rate after 2021-2023 owing to the launch of the COVID-19 vaccine and growing mental health awareness programs worldwide.

What are the Key Market Drivers in this market?

Growing prevalence of rising prevalence of mental disorders including:

  • Depression

  • Schizophrenia

  • Bipolar disorder

  • Post-traumatic stress disorder

  • Increased R&D by pharmaceutical & biopharmaceutical companies

  • Technological advancements

  • Extra Government support

  • Increase in development in healthcare infrastructure in emerging economies

There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, the leading pharmaceutical companies are investing a huge amount of money for novel drug R&D and launch. For instance, in August 2020, Janssen Pharmaceutical announced that the U.S. FDA has approved the sNDA for its SPRAVATO (Esketamine) CIII nasal spray, for the treatment of adults with MDD.

What are the Market Opportunities?
The development and discovery of new mental disorders drugs have gained valuable impetus in recent years. Drug makers are moving from conventional drug formulations to the discovery of innovative and improved medications to treat a variety of mental disorders within the mental disorder care industry. The government and other non-profit organisations are rapidly investing in the creation of new treatments for mental disorders. Collaborations between non-profit organisations and the government are on the rise in the mental disorder treatment industry, particularly in developing regions such as China and India.

The high opportunities in developing countries such as China and India will strengthen the global mental disorder drugs market in near future. The developing healthcare infrastructure along with the high prevalence of mental disorders in these countries is expected to boost the demand for advanced mental disorder drugs in these countries.
How is the Competitive Landscape shaping up?

Get Detailed TOC @ https://www.visiongain.com/report/mental-disorder-drugs-market-2021/#download_sampe_div

Mental disorder drugs market is a highly competitive market with several global and local players. Some of the major players operating in the market are AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, and Pfizer.

These leading companies have adopted various strategies comprising R&D investment, collaborations, M&A, regional expansion, and new product launches. For instance, in December 2020, Novartis announced plans to acquire Cadent Therapeutics for $210 million upfront and around $560 million in milestone payments. Cadent Therapeutics is a privately held biotechnology company that focuses on neuroscience.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Find more research reports on the Therapeutic Drugs Industry, please click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.